L01EJ Janus-associated kinase (JAK) inhibitors Janus-associated kinase (JAK) inhibitors Janus-associated kinase (JAK) inhibitors Janus-associated kinase (JAK) inhibitors L4
Source: Wikipedia · CC BY-SA 4.0 Fuente: Wikipedia · CC BY-SA 4.0 · nombre de respaldo (en) 来源:维基百科 · CC BY-SA 4.0 · 回退名 (en) 來源:維基百科 · CC BY-SA 4.0 · 回退名 (en)
ATC level L4 · Search this class · Consumer categories
Active ingredients in this class
6 active ingredients 6 principios activos 6 个活性成分 6 個有效成分
Each market now shows one aggregated status: a market counts as on sale if it has any active record; individual record statuses are shown in the details. The same market can also have several registration records with different statuses, so each market appears only once here; that is a record fact, not a safety judgement.
A missing name is marked in its row only when it is the exception; when most names lack it, the list stays unmarked.
- Ruxolitinib
L01EJ01active US GB CA AU SG · and 5 more y 5 más 另有 5 个 另有 5 個
active US GB CA AU SG ES TW EU · unknown HK - Momelotinib
L01EJ04active US GB CA AU SG · and 4 more y 4 más 另有 4 个 另有 4 個
active US GB CA AU SG ES EU · unknown HK - Fedratinib
L01EJ02Salt form: Fedratinib Hydrochloride
Fedratinib Hydrochlorideactive US GB CA AU SG · and 3 more y 3 más 另有 3 个 另有 3 個
active US GB CA AU SG ES TW EU - 硫酸艾玛昔替尼
L01EJactive CN
active CN - 戈利昔替尼
L01EJactive CN
active CN - Pacritinib
L01EJ03active US
active US
By dosage form, across markets
Only ingredients with a recorded ATC class are listed (6,009 of 12,637).